Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and
The company's director of molecular biology to participate in roundtable discussion at the "Towards an HIV Cure" symposium
DURHAM, N.C., July 17, 2015 (GLOBE NEWSWIRE) - Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a
biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer
and infectious diseases based on the ArcelisŪ technology platform, today announced Irina Tcherepanova, Ph.D., the
company's director of molecular biology, will present at the 8th International AIDS Society (IAS) Conference on HIV
Pathogenesis, Treatment and Prevention being held at the
Vancouver Convention Centre in Vancouver, British Columbia, Canada July 19-22, 2015.
Dr. Tcherepanova will participate in a roundtable discussion on combination therapy trials at the
"Towards an HIV Cure" symposium on Saturday, July 18, at 3:50pm PDT. She will also present a
poster titled, "Polyvalent immune responses correlate with lower number of HIV-infected
CD4 T cells in chronically infected subjects treated with autologous RNA pulsed DC
therapy," on Tuesday, July 21, starting at 12:30pm PDT.
The IAS Conference on HIV Pathogenesis, Treatment and Prevention features the latest HIV science,
including basic, clinical, and prevention research. It brings together a broad cross-section of HIV
professionals from around the world with a focus on moving scientific advances into practice.
For more information visit http://www.ias2015.org/.
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis ® technology platform. Argos' most advanced product candidate, AGS - 003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate Arcelis ® - based product candidate, AGS - 004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial aimed at HIV eradication in adult patients. For more information about Argos Therapeutics , visit www.argostherapeutics.com .
Source: Argos Therapeutics
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: